To investigate the therapeutic efficacy of mPEG × HER2-modified PLD to HER2-overexpressed ovarian tumor in vivo, we established SKOV-3 tumor-bearing nude mice and intravenously treated them with saline, 5 mg kg−1 PLD, mPEG × HER2 BsAb, mPEG × HER2− or mPEG × DNS-modified PLD once a week for 4 weeks and the tumor volume and body weight of tumor-bearing mice was measured twice a week. Here, ERBB2 is linked to ovarian neoplasm.